Daunorubicin

Adults: Check all parenteral products visually for particulate matter before giving them. Representative dose schedules and combination for the approved indication of remission induction in adult acute nonlymphocytic leukemia, in combination: for patients under 60 years of age, Daunorubicin 45 mg/m2/day IV on days 1, 2 and 3 of the first course and on days 1 and 2 of later courses, together with cytosine arabinoside 100 mg/m2/day by IV infusion daily for 7 days in the first course and for 5 days in later courses. For patients aged 60 years and above, Daunorubicin 30 mg/m2/day IV on days 1, 2 and 3 of the first course and on days 1 and 2 of later courses, together with cytosine arabinoside 100 mg/m2/day by IV infusion daily for 7 days in the first course and for 5 days in later courses. This reduction in the Daunorubicin dose is based on a single study and may not be appropriate where optimal supportive care is available. Representative dose schedule and combination for the approved indication of remission induction in pediatric acute lymphocytic leukemia, in combination: Daunorubicin 25 mg/m2 IV on day 1 every week, Vincristine 1.5 mg/m2 IV on day 1 every week, and prednisone 40 mg/m2 by mouth daily. A complete remission is generally achieved within four such courses of therapy. If the patient is only in partial remission after four courses, one further course, or two if necessary, may be given in an effort to achieve complete remission. In children under 2 years of age or with a body surface area below 0.5 m2, it is recommended that the Daunorubicin dose be calculated by weight (1 mg/kg) rather than by body surface area. Representative dose schedules and combination for the approved indication of remission induction in adult acute lymphocytic leukemia, in combination: Daunorubicin 45 mg/m2/day IV on days 1, 2 and 3, and Vincristine 2 mg IV on days 1, 8 and 15; prednisone 40 mg/m2/day by mouth on days 1 through 22, then tapered between days 22 and 29; L-asparaginase 500 IU/kg/day IV for 10 days on days 22 through 32. Or, as directed by the registered physician.